Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 216.45K -1.9% |
| Revenue (ttm) | 21.13M -28.9% |
| Net Income | -2.19M |
| EPS | -1.15 |
| Shares Out | 16.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,122,285 |
| Average Volume | 3,801,154 |
| Open | 0.0148 |
| Previous Close | 0.0144 |
| Day's Range | 0.0128 - 0.0148 |
| 52-Week Range | 0.0128 - 0.9600 |
| Beta | 0.74 |
| RSI | 17.41 |
| Earnings Date | Apr 28, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
IOVA: Analyst Comments on FDA Rejection Impact
IOVA: Analyst Comments on FDA Rejection Impact
Why Is Plus Therapeutics Stock Gaining Friday?
Plus Therapeutics Inc. (NASDAQ: PSTV) shares are up on Friday on continuous momentum after the company announced that the U.S. Food and Drug Administration (FDA) on Wednesday granted Orphan Drug Desi...
FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short
FDA says Replimmune melanoma therapy lacks sufficient efficacy evidence, citing trial flaws and limited data in BLA resubmission review. ... Full story available on Benzinga.com
Replimune (REPL) Faces Setback as FDA Rejects RP1 Approval Again
Replimune (REPL) Faces Setback as FDA Rejects RP1 Approval Again
Replimune (REPL) Shares Decline Following FDA Letter
Replimune (REPL) Shares Decline Following FDA Letter
What's Going On With Replimune Stock Friday?
REPL shares dive 19% as investors await a critical FDA decision on RP1 for melanoma. Will the resubmitted BLA finally secure approval today? ... Full story available on Benzinga.com
Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum
MELBOURNE, Australia — Telix Pharmaceuticals Ltd. shares surged more than 7% Friday as the Australian radiopharmaceutical company received a key regulatory boost in the United States, highlighting its...
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
On Thursday, the U.S. Food and Drug Administration (FDA) accepted Telix Pharmaceuticals Limited’s (NASDAQ: TLX) resubmitted New Drug Application (NDA) for TLX101-Px1 (Pixclara 2, Floretyrosine F 18 o...
Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent
Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent
Novel Drugs Approved By The FDA In 2025
(RTTNews) - The U.S. Food and Drug Administration (FDA) in 2025 approved 46 novel drugs, including 34 new molecular entities (NMEs) and 12 biologics. The approved drugs treated indications ranging fro...
ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA Nod as Healthcare Leads Mixed Session Amid Oil Rebound
SYDNEY — Telix Pharmaceuticals Ltd (ASX: TLX) led the S&P/ASX 200 gainers Friday with a 3.23 percent surge to $14.08 after the U.S. Food and Drug Administration accepted its resubmitted New Drug Appli...
Glenmark Secures FDA Approval For Progesterone Vaginal Inserts, 100 Mg
(RTTNews) - Glenmark Pharmaceuticals Limited (532296) has received final approval from the U.S. FDA for its Progesterone Vaginal Inserts, 100 mg, marking a new addition to the company's women's health...
Pune FDA seizes over 3,800kg of adulterated mango pulp
Pune:The Pune Food and Drug Administration (FDA) has seized over 3,800 kg of adulterated mango pulp following raids in Maval and Khed talukas.Acting o.
GSK (GSK) Withdraws Leucovorin Calcium Application from FDA
GSK (GSK) Withdraws Leucovorin Calcium Application from FDA
FDA Flags Quality System Lapses At Medline Facility Over Device Risks
FDA warns Medline over device quality lapses, citing CAPA failures, contamination risks, and unresolved syringe disconnection issues. ... Full story available on Benzinga.com
ImmunityBio Stock Climbs 7% as Record $44M Q1 Revenue from ANKTIVA Fuels Biotech Rally
Shares of ImmunityBio Inc. rose sharply midday Thursday as the commercial-stage immunotherapy company reported record preliminary first-quarter 2026 net product revenue of approximately $44.2 million ...
Vanda Pharmaceuticals (VNDA) Criticizes FDA Review Process Changes
Vanda Pharmaceuticals (VNDA) Criticizes FDA Review Process Changes
Eli Lilly Just Launched Its $149 Obesity Pill
Eli Lilly and Co . (NYSE: LLY) on Wednesday announced that Foundayo (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems. Access Expands Across Li...
Vanda Urges FDA To Withdraw Proposal Extending Drug Review Timelines
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) has called on the U.S. FDA to withdraw a legislative proposal included in the agency's FY 2027 Congressional Budget Justification.
MODD Achieves FDA Clearance for Innovative Insulin Patch Pump
MODD Achieves FDA Clearance for Innovative Insulin Patch Pump
FDA Review Looms As Replimune Faces Weak Technical Setup
Replimune awaits FDA decision on RP1 for skin cancer after initial rejection, with weak technicals and prior rejection concerns. ... Full story available on Benzinga.com
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd Inc. (NASDAQ: IVVD) shares are up during Thursday’s premarket session as the company announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody aimed at pr...
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson (NYSE: JNJ) will release earnings for its first quarter before the opening bell on Tuesday, April 14 . Analysts expect the New Brunswick, New Jersey-based company to report quarterl...
ANI Pharma Launches Isosorbide Mononitrate Tablet Following FDA Approval
(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP), a generic pharmaceutical product manufacturer, announced that following final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food ...
MacroGenics' Lorigerlimab Study In Ovarian Cancer Back On Track As FDA Lifts Clinical Hold
(RTTNews) - MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company, announced that the U. S. Food and Drug Administration (FDA) has removed the partial clinical hold on the firm's Phase ...